Latest available resultsQuarter ended June 30, 202610-Q · August 5, 2026
Filed with the SECSolventum Corp
SOLVHealthcare
Next reportNovember 4, 2026Analyst forecast 1.381 $/share
Revenue
$2.21B
▲ +2.2% vs prior year% YoY
Net income
$92.00M
▲ +2.2% vs prior year% YoY
EPS
0.53$
▲ +3.9% vs prior year% YoY
Net margin
4.2%
▲ +0.0 percentage points vs prior year pp YoY
Revenue▲ +2.2 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +2.2 %
EPS▲ +3.9 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $2.21B | |
| Gross profit | $1.29B | 58.2 % |
| Operating income | $181.00M | 8.2 % |
| Net income | $92.00M | 4.2 % |
| R&D | $178.00M | 8.1 % |
| EPS (diluted) | 0.53 $ | |
| Balance sheet | ||
| Assets | $14.24B | |
| Liabilities | $9.44B | |
| Equity | $4.80B | |
| Cash | $403.00M | |
| Capital | ||
| Shares outstanding | 170.22M | as of 2026-07-31 |
| Public float | — | |